Palo Alto Networks is reportedly in negotiations to acquire Beacon Security, a two-year-old Israeli cybersecurity startup. Beacon specializes in agentic security, developing a platform that enables AI agents to autonomously detect, investigate, and respond to cyber threats by consolidating and enriching data from various security systems. This potential acquisition aligns with Palo Alto Networks' strategy of expanding its technology portfolio through Israeli cybersecurity firms, having acquired 12 such startups since 2014.
The Japanese Yen (JPY) trades higher against the US Dollar (USD) on Thursday. In the European trade, the USD/JPY pair is down 0.3% to near 157.90. The pair faces selling pressure as the US Dollar...
Group press release In October 2025, ABB announced that it had signed an agreement to divest its Robotics division to SoftBank Group Corp. (SoftBank) for an enterprise value of $5.375...
Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.
AN2 Therapeutics, Inc. (NASDAQ: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 9:30 am GMT. The company, a clinical stage biopharmaceutical firm, will also have management available for one-on-one meetings. A webcast of the presentation will be accessible on the Investors section of the AN2 Therapeutics website.
VeriSign (VRSN) is under investor scrutiny after updating its 2026 outlook, reporting Q3 earnings, and confirming a dividend. While a common valuation narrative suggests the stock is 5.5% undervalued at $336.40, driven by anticipated price increases for .com and .net domains, a discounted cash flow model indicates it may be overvalued at $221.58. This discrepancy highlights potential differences in analyst assumptions about future growth and the longevity of VeriSign's domain economics.
The article reports on the filing of Form DEF 14A for USBC on November 5th. It is a brief financial news item from Investing.com, likely indicating a proxy statement filing related to a shareholder meeting or significant corporate action for the entity "USBC". No specific details about the content of the DEF 14A are provided beyond the filing date.
Morgan Stanley has downgraded Cisco Systems Inc. (NASDAQ:CSCO) to Equalweight from Overweight, reducing its price target due to valuation concerns, despite the stock's significant rise over the past year. The firm believes that a substantial portion of the AI-driven rerating and market-cap expansion is already reflected in the shares, leaving less room for upside from earnings growth. This decision comes even as other analysts have recently raised their price targets for Cisco, citing strong fiscal 2026 results and growth prospects.
Morgan Stanley has downgraded Ivanhoe Mines Ltd. to Equalweight from Overweight and reduced its price target due to recurring operational issues, forecasting the stock to trade below its intrinsic value until an updated mining plan is released in March 2027. The firm also lowered its adjusted EBITDA and EPS estimates for 2026, 2027, and 2028 after the company's Q3 2026 earnings missed Wall Street expectations, despite strong operational updates from its copper and zinc businesses. The stock has experienced a significant decline year-to-date and is noted for its price volatility.
Accuray reported an 8% year-over-year decline in net revenue to $86.5 million for Q1 FY27, primarily due to geopolitical challenges in China. Despite this, the company achieved a positive adjusted EBITDA of $2.5 million, a significant improvement from a $4.1 million loss in the prior year, driven by a 4% increase in service revenue and a 25% reduction in operating expenses. Product revenue fell 26%, and the book-to-bill ratio of 0.7 indicates ongoing pressure on future hardware sales.
Tokyo, Nov. 5 (Jiji Press)--Most Bank of Japan policymakers shared concern that underlying inflation could exceed the central bank's 2 pct price stability target at their Sept. 17-18 meeting, at which the BOJ...
Danaher (DHR) has seen its stock fair value increase due to analysts raising price targets, with several now between US$260 and US$275. This optimism is driven by the company's 2027 core growth projections, Q3 2026 performance, and potential for improved margins and organic growth. The revised fair value estimate for Danaher has moved from US$244.14 to US$259.90.
SOCIETYByChris Boyette, Maria Aguilar Prieto Thursday, November 5, 2026 6:18AMStream Southern California's News Leader and Original Shows 24/7A lucky Powerball ticket in New Jersey has won an estimated $847...
YETI (NYSE:YETI) is scheduled to release its Q3 2026 earnings before market open on Thursday, November 12th, with analysts expecting $0.84 EPS on $523.21 million in revenue. The company previously beat estimates in Q2 2026, reporting $0.67 EPS against a $0.54 consensus. Analysts currently rate YETI stock a "Moderate Buy" with an average price target of $55.20.
Tuesday's midterm vote is behind us, and chip stocks came into it bruised. The VanEck Semiconductor ETF (SMH -2.75%) ended Election Day at $518.52. That was around 22% under the fund's highest close ever, set...
This article details conflicting analyst sentiments for three healthcare companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP), and Travere Therapeutics (TVTX). Stifel Nicolaus analysts reiterated a Buy rating for Jazz Pharmaceuticals and Inspire Medical Systems, while maintaining a Hold rating for Travere Therapeutics. The article provides individual analyst ratings, price targets, and overall Street consensus for each company.
ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease business by adding EMCITATE, an approved treatment for MCT8 deficiency, which ANI estimates could achieve peak sales of over $300 million with patent protection extending into mid-2045. Egetis's board unanimously recommends the offer, and shareholders representing about 42% of outstanding shares have committed to accept, with the deal contingent on 90% shareholder acceptance and regulatory approvals.
Mergers And AcquisitionsLife SciencesFinanceANIPJPM
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.
USBC, Inc. has filed a Transition Report on Form 10-K for the quarter spanning October 1, 2025, to December 31, 2025, reflecting its fiscal year end adjustment from September 30 to December 31, effective fiscal year 2026. The report details the company's change to a calendar-year reporting structure to align with operational cycles and industry peers. It also highlights 388,144,429 outstanding shares, a non-affiliate market value of $14,110,017, and mentions its "tokenized cryptocurrency treasury strategy" and Bitcoin holdings.
Newmont CEO Natascha Viljoen, a South African mining engineer, disposed of 25,780 shares in the company valued at approximately $2.9 million between late October and early November. The majority of these shares were withheld for tax purposes related to restricted stock units vesting, with a smaller portion sold under a pre-arranged trading plan. Despite the sales, Viljoen retains a substantial stake in Newmont, worth about $11 million.
Argus has raised its price target for Tenet Healthcare Corporation (THC) to $293.00, citing the company's strong position in healthcare services. As of November 4, 2026, THC's current price is $292.25. Tenet Healthcare operates 47 acute and specialty hospitals and over 500 ambulatory surgery centers across the U.S., predominantly in the South.
Shares of Trump Media & Technology Group Corp., the owner of Truth Social in which President Donald Trump holds a 41% stake, fell to a record low on Wednesday after Republicans lost control of both...